The American Society of Clinical Oncology’s (ASCO) recently published antiemetic guideline update excluded oncology pharmacists from the targeted audience. A letter to the Editor was submitted to the Journal of Clinical Oncology by the Canadian Association of Pharmacy Oncology (CAPhO), in collaboration with HOPA and ISOPP, to bring awareness to the omission.